Background: Sepsis-induced myocardial dysfunction (SIMD) has a significant contribution to sepsis-caused death in critically ill patients. In recent years, the number of published articles related to SIMD has increased rapidly. However, there was no literature that systematically analyzed and evaluated these documents. Thus, we aimed to lay a foundation for researchers to quickly understand the research hotspots, evolution processes and development trends in the SIMD field via a bibliometric analysis.Methods: Articles related to SIMD were retrieved and extracted from the Web of Science Core Collection on July 19th, 2022. CiteSpace (version 6.1.R2) and VOSviewer (version 1.6.18) were used for performing visual analysis.Results: A total of 1,076 articles were included. The number of SIMD-related articles published each year has increased significantly. These publications mainly came from 56 countries, led by China and the USA, and 461 institutions, but without stable and close cooperation. As authors, Li Chuanfu published the most articles, while Rudiger Alain had the most co-citations. Shock was the journal with the most studies, and Critical Care Medicine was the most commonly cited journal. All keywords were grouped into six clusters, some of which represented the current and developing research directions of SIMD as the molecular mechanisms.Conclusion: Research on SIMD is flourishing. It is necessary to strengthen cooperation and exchanges between countries and institutions. The molecular mechanisms of SIMD, especially oxidative stress and regulated cell death, will be critical subjects in the future.

There is still a lack of effective treatment for sepsis-induced myocardial dysfunction (SIMD), while the pathogenesis of SIMD still remains largely unexplained. RNA sequencing results (GSE267388 and GSE79962) were used for cross-species integrative analysis. Bioinformatic analyses were used to delve into function, tissue- and cell- specificity, and interactions of genes. External datasets and qRT-PCR experiments were used for validation. L1000 FWD was used to predict targeted drugs, and 3D structure files were used for molecular docking. Based on bioinformatic analyses, ten differentially expressed genes were selected as genes of interest, seven of which were verified to be significantly differential expression. Bucladesine was considered as a potential targeted drug for SIMD, which banded to seven target proteins primarily by forming hydrogen bonds. It was considered that Cebpd, Timp1, Pnp, Osmr, Tgm2, Cp, and Asb2 were novel disease genes, while bucladesine was a potential therapeutic drug, of SIMD.

We describe a novel minimally invasive technique, transapical transcatheter device closure of relapse left ventricular diverticulum (LVD) under transesophageal echocardiography (TEE) guidance. The patient previously underwent LVD primary repair and mitral valvular replacement. The anatomical characteristics of the relapse LVD and its adjacent structures are detailedly delineated by echocardiography. The relapse LVD is then managed by transapical transcatheter device closure under TEE guidance. This novel minimally invasive technique is not only limited in relapse LVD, but also could be extensively applied in other cardiac reoperation, such as perivalvular leak closure after valvular replacement.

Mitral valve prolapse (MVP), defined as toward displacement of one or both mitral valve leaflets into the left atrium in systole, is a common valve disease that affects nearly 2–3% of the population. ¹ Studies have found that about 35–50% of MVP cases have a positive family history, and the strong familial aggregation of MVP suggests a clear heritable component. ² However, the genetic etiology for most non-syndromic MVP remains poorly characterized. Recently, Durst et al. ² identified two heterozygosis missense variants in the DCHS1 gene, segregated fully with MVP in 3 unrelated families. In vitro and in vivo experiments found that DCHS1 has a critical role in the valve’s morphogenesis and confirmed that loss of function of this gene results in MVP.

Ventricular septal defect (VSD) is a prevalent congenital cardiac anomaly. By enhancing the occluder design and optimizing procedural approaches, the indications for VSD closure can be broadened while minimizing associated complications. The utilization of fully biodegradable occluder holds promising potential in resolving conduction block issues encountered during VSD closure. This study aims to compare the results of the fully biodegradable occluder with the metal occluder in transoesophageal echocardiography-guided VSD closure via lower sternal level minor incision at the interim follow-up, and to find risk factors for the occurrence of electrocardiographic and valvular abnormalities postoperatively. We reviewed the postoperative and 3-year follow-up data of all patients who underwent the randomized controlled study of VSD closure from January 1 to November 7, 2019 in the Second Xiangya Hospital of Central South University. The safety and efficacy of the procedure were assessed and compared between the 2 groups by electrocardiogram and echocardiography results, and the risk factors for the occurrence of postoperative electrocardiogram and valve abnormalities were studied with Logistic regression analysis. Twelve and fifteen patients underwent VSD closure with the metallic occluder and the fully biodegradable occluder, respectively. All patients survived during the follow-up period without major complications such as atrioventricular block, significant residual shunt, too rapid absorption of the occluder, and significant valvular regurgitation. There were no significant differences in the results of electrocardiograph and color Doppler ultrasonography the metal occluder group and the fully biodegradable occluder group 1, 2, and 3 years after operation (all P>0.05). The size of the occluder were risk factors for tricuspid regurgitation at 2 and 3 years postoperatively, and the difference between the occluder size and the VSD defect size were risk factors for tricuspid regurgitation at 2 years postoperatively (P<0.05). This study adequately demonstrates the safety and efficacy of fully biodegradable occluders in small VSD closure and shows the same postoperative effects as conventional nitinol occluders.

Background: As survival after treatment for congenital heart disease (CHD) continues to improve, long-term outcomes beyond survival have become increasingly important. Evidence from mainland China remains limited, particularly for school-aged children and adolescents after treatment for CHD. This study evaluated health-related quality of life (HRQoL), depressive symptoms, and self-esteem in this population. Methods: This online cross-sectional comparative study included children and adolescents aged 7–18 years who had undergone surgical or minimally invasive treatment for CHD at least 6 months previously and controls of comparable age without known CHD or other reported chronic medical conditions. HRQoL was assessed using the Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL 4.0), depressive symptoms using the Center for Epidemiologic Studies Depression Scale for Children (CES-DC), and self-esteem using the Rosenberg Self-Esteem Scale (RSES). Continuous variables were summarized as median (interquartile range, IQR), and between-group comparisons were performed using non-parametric tests. Age- and sex-adjusted linear regression models were fitted for the major outcomes. Results: A total of 78 post-treatment CHD patients and 90 controls were included. Compared with controls, post-treatment CHD patients had lower PedsQL 4.0 scores across Physical, Emotional, Social, and School Functioning domains, as well as Physical Health, Psychosocial Health, and Total Scores (all P < 0.001). In the age- and sex-adjusted model, controls had a higher PedsQL Total Score than post-treatment CHD patients (B = 13.31, 95% CI: 8.25–18.36, P < 0.001). No statistically significant difference in CES-DC scores was observed between groups [10.5 (3.25–17.75) vs. 8.0 (4.0–14.0), P = 0.285]. RSES scores were lower in post-treatment CHD patients than in controls [31.0 (28.0–36.75) vs. 36.0 (30.0–39.0), P = 0.001]. The adjusted model also showed higher RSES scores among controls (B = 2.83, 95% CI: 1.17–4.48, P = 0.001). Conclusion: In this online sample, school-aged children and adolescents after treatment for CHD reported poorer HRQoL and lower global self-esteem scores than controls without known CHD. No statistically significant difference in depressive symptom scores was observed. These findings support post-treatment care models that extend beyond cardiac status and incorporate functional recovery, school participation, family education, physical activity guidance, and psychosocial screening.